Patients with glucocorticoid-induced osteoporosis on romosozumab show greater gains in lumbar spine bone mineral density than those on denosumab and comparable gains with those on teriparatide.

A 3-month course of romosozumab followed by denosumab provides similar BMD gains to those seen with 12 months of romosozumab in women with postmenopausal osteoporosis.

The arterial vasculature is the second most frequently calcified structure in the human body after the skeleton. Calcification of the aorta and aortic valves occurs in most individuals in westernized ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

After teasing a new regulatory process for personalized genetic medicines at the end of last year, the FDA today unveiled draft guidance for an approval pathway that could see custom CRISPR therapies, ...

The Food and Drug Administration Monday unveiled the details of a new policy designed to make it easier and quicker for patients with very rare diseases to get cutting-edge treatments. The new ...